This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Comment: Haloperidol may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. haloperidol will increase the level or effect of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. indinavir will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use of a CYP3A4 inhibitor may decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects. Minor/Significance Unknown. unspecified interaction mechanism. Use Caution/Monitor. Use Caution/Monitor. Monitor for signs of opioid withdrawal. Contraindicated. Avoid or Use Alternate Drug.Minor (1)haloperidol will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. The frequency of IM administration should be determined by patient response and may be given as often as every hour. haloperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Monitor Closely (1)gilteritinib and haloperidol both increase QTc interval. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Avoid or Use Alternate Drug. Use Caution/Monitor. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. Serious - Use Alternative (2)haloperidol and artemether/lumefantrine both increase QTc interval. Applies only to oral form of both agents. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. Use Caution/Monitor.oxycodone and haloperidol both increase sedation. haloperidol increases effects of belladonna and opium by pharmacodynamic synergism. Monitor naldemedine for potential adverse effects if coadministered with strong or moderate CYP3A4 inhibitors. Monitor Closely (5)haloperidol will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor.haloperidol and olanzapine both increase QTc interval. Modify Therapy/Monitor Closely. Applies only to oral form of both agents. Monitor Closely (1)quazepam and haloperidol both increase sedation. Use of a CYP3A4 inhibitor may decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects. Minor/Significance Unknown. Use Caution/Monitor.fesoterodine decreases levels of haloperidol by pharmacodynamic antagonism. haloperidol will increase the level or effect of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)haloperidol increases and phendimetrazine decreases sedation. Use Caution/Monitor. Monitor Closely (2)haloperidol decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. clonazepam and haloperidol both increase sedation. haloperidol increases effects of diphenhydramine by pharmacodynamic synergism. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. meperidine and haloperidol both increase sedation. haloperidol increases effects of trihexyphenidyl by pharmacodynamic synergism. triprolidine and haloperidol both increase sedation. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. pentazocine and haloperidol both increase sedation. Use Caution/Monitor. Closely monitor for evidence of enhanced CNS depression when using higher dose of magnesium sulfate together with a CNS depressant. Use Caution/Monitor. Use Caution/Monitor.haloperidol and olanzapine both increase sedation. After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib. Use Caution/Monitor. Use Caution/Monitor. Contraindicated. vecuronium decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Haldol Dosage Generic name: Haloperidol lactate 5mg in 1mL Dosage form: injection Drug class: Miscellaneous antipsychotic agents Medically reviewed by Drugs.com. Avoid or Use Alternate Drug. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Closely monitor for increased neuromuscular blockade. Monitor Closely (1)haloperidol and fostemsavir both increase QTc interval. Additive anticholinergic effects, possible hypoglycemia. dipipanone and haloperidol both increase sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)thioridazine and haloperidol both increase QTc interval. Moderate disease, 0.5-2 mg q8-12hr initially, Severe disease, 3-5 mg q8-12hr initially; not to exceed 30 mg/day, 2-5 mg q4-8hr PRN; may require q1hr in acute agitation; not to exceed 20 mg/day, Initial: IM dose 10-20 times daily PO dose administered monthly; not to exceed 100 mg; if conversion requires initial dose >100 mg, administer in 2 injections (eg, 100 mg initially, then remainder in 3-7 days), Maintenance: Monthly dose 10-15 times daily PO dose, May be needed for ICU delirium; use only haloperidol lactate for IV administration; do not use haloperidol decanoate, 2-10 mg initially, depending on degree of agitation; if response inadequate, may repeat bolus q15-30min, sequentially doubling initial bolus dose; when calm achieved, administer 25% of last bolus dose q6hr; taper dose after patient is controlled, Monitor ECG and QT interval (QT prolongation may occur with cumulative doses 35 mg; torsades de pointes reported with single doses 20 mg), calcium/magnesium/potassium/sodium oxybates, elvitegravir/cobicistat/emtricitabine/tenofovir DF, sodium sulfate/?magnesium sulfate/potassium chloride, sodium sulfate/potassium sulfate/magnesium sulfate, Neuroleptic malignant syndrome (NMS; infrequent but serious), Orthostatic hypotension (after IM injection), tachycardia, Agitation, anxiety, cerebral edema, depression, dizziness, euphoria, headache, insomnia, poikilothermia, restlessness, weakness, confusion, Anorexia, constipation, dyspepsia, ileus, decreased gag reflex, Rodents given 2- 20 times usual maximum human dose by oral or parenteral routes showed increase in incidence of resorption, reduced fertility, delayed delivery and pup mortality; no teratogenic effect reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given 15 times usual maximum human dose, Rats or rabbits administered oral haloperidol at doses of 0.5 to 7.5 mg/kg, which are approximately 0.2 to 7 times maximum recommended human dose (MRHD) of 20 mg/day based on mg/m, Cleft palate observed in mice administered oral haloperidol at dose of 0.5 mg/kg, which is approximately 0.1 times MRHD based on mg/m2 body surface area. Monitor Closely (3)homatropine decreases levels of haloperidol by inhibition of GI absorption. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment. Serious - Use Alternative (2)fentanyl intranasal, haloperidol. ciprofloxacin and haloperidol both increase QTc interval. haloperidol and ziconotide both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)ribociclib and haloperidol both increase QTc interval. Use Caution/Monitor. Use Caution/Monitor.Serious - Use Alternative (1)paroxetine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. Use Caution/Monitor.aripiprazole and haloperidol both increase QTc interval. oxybutynin topical decreases effects of haloperidol by pharmacodynamic antagonism. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended. Coadministration of sufentanil SL with any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase or prolonged adverse effects, including potentially fatal respiratory depression.Serious - Use Alternative (1)sufentanil SL, haloperidol. haloperidol and olanzapine both increase QTc interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. 2-5mg IM every 4-8hrs or up to hourly if needed; max: 20mg/day. propantheline decreases levels of haloperidol by inhibition of GI absorption. Use Caution/Monitor.Serious - Use Alternative (1)perphenazine and haloperidol both increase QTc interval. dantrolene and haloperidol both increase sedation. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor.mirtazapine and haloperidol both increase QTc interval. This drug is available at the lowest co-pay. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor Closely (1)rolapitant will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (3)oxybutynin topical decreases effects of haloperidol by pharmacodynamic antagonism. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. chloroquine increases toxicity of haloperidol by QTc interval. Monitor Closely (1)haloperidol increases and midodrine decreases sedation. If necessary it can be repeated in at least one hour. oliceridine, haloperidol. Additive anticholinergic effects, possible hypoglycemia. Monitor Closely (1)haloperidol and gemifloxacin both increase QTc interval. Use Caution/Monitor. If you are using the liquid form of the medication, use the measuring dropper provided in the package to measure your dose. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. lumefantrine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. Additive anticholinergic effects, possible hypoglycemia. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. Medically reviewed by Drugs.com. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Use Caution/Monitor. Monitor Closely (1)carisoprodol and haloperidol both increase sedation. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. haloperidol will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. promethazine and haloperidol both increase sedation. Decrease acalabrutinib dose to 100 mg once daily if coadministered with a moderate CYP3A inhibitor. Get medical help right away if you have any of the following symptoms: fever, muscle stiffness/pain/tenderness/weakness, severe tiredness, severe confusion, sweating, fast/irregular heartbeat, dark urine, signs of kidney problems (such as change in the amount of urine).In rare cases, haloperidol may increase your level of a certain chemical made by the body (prolactin). This medicine is available only with your doctor's prescription. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. Avoid or Use Alternate Drug. provider for the most current information. haloperidol increases effects of fesoterodine by pharmacodynamic synergism. Avoid or Use Alternate Drug. 1HALDOL is indicated for the control of tics and vocal utterances of Tourette's Disorder. Canada residents can call a provincial poison control center. Use Caution/Monitor. Use Caution/Monitor.haloperidol increases effects of rapacuronium by pharmacodynamic synergism. Consider dose reduction of sensitive CYP3A4 substrates. haloperidol decreases effects of methyldopa by pharmacodynamic antagonism. Monitor for hypotension, respiratory depression, and profound sedation. Avoid or Use Alternate Drug. Minor/Significance Unknown. orphenadrine and haloperidol both increase sedation. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Use Caution/Monitor.atracurium decreases levels of haloperidol by pharmacodynamic antagonism. After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). Monitor Closely (1)sodium sulfate/?magnesium sulfate/potassium chloride increases effects of haloperidol by unknown mechanism. Use Caution/Monitor.haloperidol increases and methamphetamine decreases sedation. methscopolamine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. Effect of interaction is not clear, use caution. Additive anticholinergic effects, possible hypoglycemia. trimipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval. Avoid or Use Alternate Drug. Monitor Closely (2)marijuana will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction). clarithromycin will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. histrelin increases toxicity of haloperidol by QTc interval. Use Caution/Monitor. peginterferon alfa 2b, haloperidol. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: a certain severe nervous system problem (severe CNS depression), Parkinson's disease, bipolar disorder, difficulty urinating (for example, due to prostate problems), glaucoma, heart problems (such as angina), overactive thyroid (hyperthyroidism), seizures, low white blood cell count.Haloperidol may cause a condition that affects the heart rhythm (QT prolongation). Use Caution/Monitor. Minor (1)cyclophosphamide will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Additive anticholinergic effects, possible hypoglycemia. Use Caution/Monitor.haloperidol and clozapine both increase QTc interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors. Use Caution/Monitor. Monitor Closely (2)atomoxetine and haloperidol both increase QTc interval. chloroquine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Monitor Closely (1)sulfamethoxazole and haloperidol both increase QTc interval. Strong or moderate CYP3A4 inhibitors may increase systemic concentration of norgestrel, which may increase risk for adverse effects. Monitor Closely (1)levomilnacipran, haloperidol. unspecified interaction mechanism. Minor (1)indomethacin increases toxicity of haloperidol by unknown mechanism. haloperidol increases and phenylephrine PO decreases sedation. haloperidol and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Use Caution/Monitor. unspecified interaction mechanism. haloperidol will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. haloperidol increases effects of oxybutynin by pharmacodynamic synergism. Elderly patients with dementia -related psychosis treated with antipsychotic drugs are . Monitor Closely (1)ciprofloxacin and haloperidol both increase QTc interval. The total parenteral dose in the preceding 24 hours may be used to approximate an initial oral total daily dose. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely. Use Caution/Monitor.haloperidol and venlafaxine both increase QTc interval. Use Caution/Monitor.haloperidol and ritonavir both increase QTc interval. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Use Caution/Monitor. haloperidol decreases effects of safinamide by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor.atropine decreases levels of haloperidol by pharmacodynamic antagonism. haloperidol and artemether both increase QTc interval. belladonna and opium decreases levels of haloperidol by pharmacodynamic antagonism. rocuronium decreases levels of haloperidol by pharmacodynamic antagonism. Monitor Closely (1)lenacapavir will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Serious - Use Alternative (1)haloperidol decreases effects of pramipexole by pharmacodynamic antagonism. chlorzoxazone and haloperidol both increase sedation. haloperidol and lofexidine both increase sedation. Avoid or Use Alternate Drug. ketoconazole will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. QTc interval. Additive anticholinergic effects, possible hypoglycemia. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. bosutinib and haloperidol both increase QTc interval. Mechanism: pharmacodynamic synergism. Severe symptomology: 3 to 5 mg orally 2 to 3 times a day. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics. Minor/Significance Unknown. Use Caution/Monitor. Use Caution/Monitor.primidone will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Effect of interaction is not clear, use caution. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a strong/moderate CYP2D6 inhibitor.brexpiprazole and haloperidol both increase sedation. EPS risk. cyclobenzaprine decreases levels of haloperidol by pharmacodynamic antagonism. haloperidol and procainamide both increase QTc interval. QTc interval. Use Caution/Monitor. Use Caution/Monitor. oxaliplatin will increase the level or effect of haloperidol by Other (see comment). oxybutynin decreases levels of haloperidol by inhibition of GI absorption. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. ivosidenib will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Applies only to oral form of both agents. Avoid or Use Alternate Drug.
Falcon Ridge Golf Club,
Small Commercial For Sale In Lahore,
Articles H